Ultimovacs ASA: Third quarter 2021 result presentation

NEXT STORY
Allarity Therapeutics’ Oral PARP Inhibitor, Stenoparib, Demonstrates Pre-clinical Antiviral Activity Against Delta Variant of Coronavirus
PREV STORY
Dr. Tina Koopersmith Demystifies Desire with Blueprints Coaching
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Akari Therapeutics Receives FDA Fast Track Designation for Nomacopan for Pediatric Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA)

author_avatar
NASDAQ Market News

Preliminary results suggest nearly 6% of Montreal children tested from October to April had antibodies to SARS-CoV-2

author_avatar
NASDAQ Market News

TG Therapeutics Enters into a Global Collaboration to Develop and Commercialize Novel BET Inhibitors Developed by Jubilant Biosys for the Treatment of Hematological Malignancies

NEW YORK, May 27, 2016 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (Nasdaq:TGTX), announced today that ...

author_avatar
NASDAQ Market News